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Summary
Background: The aim of this study was to examine the effects of gastric medicines
on gastroduodenal injury during antiplatelet therapy after coronary intervention.
Methods: A total of 501 patients were enrolled and as dual antiplatelet ther-
apy, aspirin and thienopyridine were administered. Patients were divided into four
groups: histamine H2-receptor antagonists (H2RA); proton pump inhibitors (PPI);
other gastromucosal protective agents (GMP); or nothing (None), and follow-up
lasted 8—20 months.
Results: H2RA were prescribed in 212 cases (42%), PPI in 150 (30%), GMP in 56 (11%),
and None in 83 (17%). Signiﬁcant ﬁndings by endoscopy were recognized in 18 cases
and upper gastrointestinal bleeding requiring hospitalization occurred in 7 patients
(1.4%; H2RA in 4, GMP in 2, and None in 1). There were no gastrointestinal injuries
in the PPI group. To minimize the effect of selection bias on gastroduodenal lesions,
the propensity score analysis for clinical characteristics was used. The results of
propensity score matching showed that administration of PPI reduced the incidence
of gastrointestinal lesions compared with that of the non-PPI group.
Conclusion: Administration of PPI reduced the incidence of gastrointestinal lesions
compared with that of the non-PPI group.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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to conﬁrm that the groups had been successfully
matched. We calculated the incidences of gastro-
duodenal ulcer and gastritis/duodenitis conﬁrmed72
Introduction
It is widely accepted that antiplatelet therapy has
preventive effects against cardiovascular events in
patients with coronary artery disease (CAD) [1].
In cases of deployment of drug-eluting stents,
dual antiplatelet therapy is continued at least for
about 6 months post-stent in many hospitals [2].
Aspirin, which is a non-steroidal anti-inﬂammatory
drug, and also other antiplatelet agents have been
reported to have gastrointestinal toxicity that lim-
its their use [3]. It remains unclear which is an
appropriate and effective medicine for inhibit-
ing gastrointestinal injury in patients with CAD
after percutaneous coronary intervention (PCI).
Thus, the aim of this study was to examine
the preventive effects of gastric agents against
gastroduodenal injury in patients on antiplatelet
therapy.
Methods
Subjects
A total of 501 patients who underwent PCI for
diagnosis of stable angina in our institutes during
2007 were enrolled in this analysis (male 341 cases,
mean age 71 years) and background characteristics
including the prescribed medications in all of these
cases were retrospectively ascertained from med-
ical records. As dual antiplatelet therapy, aspirin
100mg/day and ticlopidine 200mg/day, or clopido-
grel 75mg/day were administered. The selection of
gastric agents was determined by each attending
physician. Patients were divided into four groups:
histamine H2-receptor antagonists (H2RA); proton
pump inhibitors (PPI); other gastromucosal protec-
tive agents (GMP); or nothing (None). The study
protocol was in agreement with the guidelines of
the ethical committee of the institution and written
informed consent was obtained from each patient
or the family of the subject.
Angioplasty procedure
PCI was performed according to the standard tech-
nique, and in one vessel per patient. Conventional
treatment was given during angioplasty, including
isosorbide dinitrate and heparin. Additional hep-
arin was administered each hour in long procedures.
The technical aspects of the procedure, includ-
ing the choice of stent and balloon, duration of
inﬂation and pressure, were determined by each
operator.
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ndoscopy
n cases complaining of upper gastrointestinal
ymptoms, endoscopic examination was performed
ccording to the standard technique. Gastroduo-
enal injury was deﬁned as obvious ﬁndings of
lcer or erosion including bleeding, but excluding
sophageal lesions, atrophic gastritis, and malig-
ancies.
eﬁnitions and follow-up
ypertension was deﬁned as systolic blood pres-
ure >140mmHg or diastolic pressure >90mmHg.
iabetic mellitus was deﬁned according to World
ealth Organization (WHO) criteria. Patients were
ollowed by hospital visits or telephone interview,
nd if necessary, the examination of gastrointesti-
al endoscopy was advised.
tatistical analysis
tatistical analysis was performed as follows. All
alues are expressed as mean± S.D. Statistical
nalysis of the differences in clinical charac-
eristics among the four groups was performed
sing Wilcoxon nonparametric test or chi-square
est.
ropensity score analysis
n an additional effort to balance the patient
roups, we used propensity score analysis to gen-
rate a set of matched cases (patients with PPI
dministration) and controls (patients without PPI
dministration), as previously described [4]. The
ropensity score was calculated for each patient
ased on a logistic regression analysis of the
robability of PPI prescription using clinical char-
cteristics. With these propensity scores, we then
sed a greedy matching technique to create a 1-
o-1 match of cases with controls as described by
arsons [5]. Comparisons between the two matched
roups based on clinical characteristics were car-
ied out using chi-square test or unpaired t-testy endoscopy between the two matched groups.
P-value <0.05 was deﬁned as statistical signiﬁ-
ance.
All analyses were performed using the SAS soft-
are package version 9.1 (SAS, Cary, NC, USA).
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Table 1 Patient characteristics.
H2RA PPI GMP None Total P
Number 212 (42%) 150 (30%) 56 (11%) 83 (17%) 501 n.s.
Sex (M/F) 140/72 101/49 37/19 58/25 336/165 n.s.
Age (mean± S.D.) 69± 10 72± 9 71± 8 68± 9 70.5± 9.7 0.03
Hypertension 109 (51%) 85 (57%) 31 (55%) 34 (41%) 259 (52%) n.s.
Diabetes 61 (29%) 52 (35%) 12 (21%) 23 (27%) 148 (30%) n.s.
Prior GD lesion 7 (3.3%) 15 (10%) 2 (3.6%) 0 24 (4.8%) 0.003
Hemodialysis 7 (3.3%) 8 (5.3%) 3 (8.9%) 2 (2.4%) 22 (4.4%) n.s.
Antiplatelet therapy
Aspirin alone 6 6 1 2 15 (3%) n.s.
Asp + thienopyridine 196 141 54 74 465 (93%) n.s.
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H2RA, histamine H2-receptor antagonists; PPI, proton pump inh
Asp, aspirin. Data are presented as the mean± S.D.
esults
he clinical characteristics of each group are shown
n Table 1. Stomach medicines were H2RA in 212
ases (42%), PPI in 150 (30%), GMP in 56 (11%),
nd None in 83 (17%). There were signiﬁcant dif-
erences in age and prior gastroduodenal lesions
mong the four groups, and it seemed that the
PI group had higher age and higher incidence of
rior gastrointestinal lesions. Antiplatelet thera-
ies at discharge were aspirin alone in 15 patients,
spirin + thienopyridine in 465, and aspirin + other
latelets in 21. Follow-up lasted 8—20 months. Gas-
roduodenal endoscopy was performed in 31 of the
01 cases (6.2%), and the reasons for undergoing
ndoscopy were upper abdominal symptoms such
s epigastric pain, discomfort, early satiety after
ating, or bloating, and follow-up study of prior
astrointestinal diseases. As shown in Table 2, sig-
iﬁcant ﬁndings were recognized in a total of 18 of
he 31 cases and details were 10 in H2RA (4.7%),
in PPI (1.3%), 3 in GMP (5.4%), and 3 in None
roup (3.6%), respectively. Although special treat-
ent including hospitalization was needed in seven
atients (four in H2RA, two in GMP, and one in
one groups), there was no severe gastrointesti-
D
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Table 2 Gastroduodenal lesions.
H2RA PPI
Number 212 150
Endoscopy done 10 (4.7%) 15 (10
Gastroduodenal lesions 10 (4.7%) 2 (1.
Gastroduodenal ulcer 3 0
Gastritis/duodenitis 7 2
Hospitalization 4 0
Blood transfusion 0 0
H2RA, histamine H2-receptor antagonists; PPI, proton pump inhibit1 7 21 (4%) n.s.
r; GMP, gastric mucosal protective agent; GD, gastroduodenal;
al injury in the PPI group (Table 3). Two cases
equired blood transfusion in the GMP and None
roups. Five of the seven patients experienced gas-
rointestinal injury within 2 months, and the lesions
ere detected within a maximum of 6 months in
ll subjects. In terms of antiplatelet therapy, six
atients were taking aspirin and thienopyridine,
nd one aspirin alone (case no. 7 in Table 3). To min-
mize the effect of selection bias on gastroduodenal
esions, the propensity score matching for clini-
al characteristics such as age, sex, hypertension,
iabetes, prior gastroduodenal lesion, or hemodial-
sis, was used. In the present study, 143 cases
ere successfully matched in a 1:1 manner with
43 corresponding controls (Table 4). The results of
ropensity score matching showed that administra-
ion of PPI reduced the incidence of gastrointestinal
esions and hospitalization necessitating special
reatment compared with the non-PPI group
Table 4).iscussion
n Japan compared with western countries,
2RA are more popular than PPI for cardiologists as
GMP None Total
56 83 501
%) 3 (5.4%) 3 (3.6%) 31 (6.2%)
3%) 3 (5.4%) 3 (3.6%) 18 (3.6%)
1 1 5
2 2 13
2 1 7 (1.4%)
1 1 2
ors; GMP, other gastromucosal protective agents.
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Table 3 Details of seven patients requiring hospitalization.
Case no. Age Sex Gastric agent Duration Findings Comorbidity
1 86 M H2RA 2M Gastric ulcer
2 70 M H2RA 2M Erosive gastritis
3 86 M GMP 5M Erosive gastritis
4 73 F GMP 6M Erosive gastritis HD
5 77 F H2RA 1M Gastric ulcer DM
6 70 M H2RA 1W Erosive gastritis HT, LZ
onist;
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p7 45 M None
M in Sex, male; F, female; H2RA, histamine H2-receptor antag
W, week; HD, hemodialysis; DM, diabetes mellitus; HT, hyperte
prophylactic administration against gastroduodenal
mucosal injury during antiplatelet therapy [6]. Gas-
tric damage associated with the use of antiplatelet
agents occurred not only in the GMP group but also
in the H2RA group, however, not in the PPI group
in this study. Thus, as well as previous reports, PPI
may be more appropriate and effective than H2RA
in healing and preventing ulcers during antiplatelet
therapy [7]. As shown in Table 1, the rate of prior
gastroduodenal lesions was highest in the PPI group
(15/150, 10%). Although the frequency of H2RA
use was the highest among the gastric agents in
the present study, the detailed examination of
medical records revealed the preferred use of PPI
in cases of prior gastroduodenal injury or upper
gastrointestinal surgical operation. Despite this
difﬁcult situation with high risk of occurrence or
recurrence of upper gastrointestinal lesions, there
were no serious cases requiring hospitalization in
the PPI group. Moreover, to minimize the effect of
selection bias on outcomes, we used the technique
u
t
b
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Table 4 Patient characteristics and outcomes between the
PPI
Number 143
Sex (M/F) 94/49
Age (mean± S.D.) 72± 10
Hypertension 78 (55%)
Diabetes 46 (32%)
Prior GD lesion 8 (6%)
Hemodialysis 8 (6%)
Antiplatelet therapy
Aspirin alone 6 (4%)
Asp + thienopyridine 134 (94%)
Asp + others 3 (2%)
Outcomes
Endoscopy done 8 (6%)
Gastroduodenal lesions 1 (1%)
Hospitalization 0
Blood transfusion 0
PPI, proton pump inhibitor; Asp, aspirin. Data are presented as the1M Gastric ulcer HD
GMP, gastromucosal protective agent; M in Duration, month;
n; LZ, liver cirrhosis.
f propensity score matching for clinical charac-
eristics and excluded distortion of confounding
actors. Based on propensity score analysis, PPI
reatment reduced signiﬁcantly the incidence of
astroduodenal damage and hospitalization neces-
itating special treatment compared with non-PPI
reatment. There have been no studies that show a
eduction in the risk of upper gastrointestinal injury
n stable angina patients with the use of PPI, thus
hese results may indicate the efﬁcacy of PPI ther-
py after PCI for protection against gastroduodenal
njuries. Yamamoto et al. [8] showed the incidence
f gastroduodenal mucosal injury and bleeding in
atients on antiplatelet therapy and 75% of all
atients (262/350) were on aspirin alone. Moreover,
lthough the report by Chin et al. [9] demonstrated
redictive and protective factors associated with
pper gastrointestinal bleeding after PCI, most of
he patients had acute coronary syndrome, not sta-
le angina. In this study, patients with stable angina
ere examined as subjects, and the rate of aspirin
PPI and non-PPI groups after propensity score matching.
Non-PPI P
143 n.s.
99/44 n.s.
71± 10 n.s.
79 (55%) n.s.
37 (26%) n.s.
8 (6%) n.s.
7 (5%) n.s.
4 (3%) n.s.
131 (92%) n.s.
8 (6%) n.s.
12 (8%) n.s.
12 (8%) 0.002
6 (4%) 0.01
1 (1%) n.s.
mean± S.D.
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lone was 3% (15/501) and most patients (465/501,
3%) were on dual antiplatelet therapy, such as
spirin and thienopyridine. From the viewpoint of
ubjects, this is the ﬁrst manuscript reporting the
isk reduction of upper gastrointestinal injury in
atients with stable angina on dual antiplatelet
herapy.
Although we used the technique of propen-
ity score matching between the PPI and non-PPI
roups, there are some limitations to this study,
uch as retrospective, small number, and bias by
ttending physician in selection of gastric medica-
ion, moreover, upper gastrointestinal endoscopy
as not performed in all patients, and the num-
er of cases studied by endoscopy was very small.
urthermore, high-age patients may not complain
bout upper gastrointestinal symptoms, and there
ay be a possibility to miss those patients, and
e excluded the relationship between antiplatelet
herapy and malignancy. However, these results
rovide useful information regarding gastroduo-
enal injury in patients with chronic CAD on
ntiplatelet therapy. Considering the importance
f antiplatelet therapy in not only CAD but
lso atherothrombotic diseases, further prospec-
ive study is needed in the future.
Finally, the relation between heart and stom-
ch has been sporadically reported until now; for
xample, inferior myocardial infarction may be
rongly diagnosed as upper gastrointestinal dis-
ase due to the symptoms of vomiting and nausea
10], and we reported a case of angina-like disease
ue to cardiac compression by a giant hiatal hernia
11]. In the present study, we suggested the risk
f gastroduodenal injury during antiplatelet ther-
py in patients with CAD. Considering that these
ndings drew cardiologists’ attention to the inter-
ction between heart and stomach in the broad
ense, we propose an idea of ‘‘cardio-gastric link-
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